10-Q: ProMIS Neurosciences Q3 Loss, Funding, Going Concern Warning

ProMIS Neurosciences reported a significant net loss in Q3 2025, raising capital through warrant exercises and offerings, but faces substantial doubt about its ability to continue as a going concern.

Summary

• Net loss for the nine months ended September 30, 2025, was $29.0 million, a significant increase from a $3.0 million net income in the same period of 2024.
• Operating losses for the nine months ended September 30, 2025, were $29.4 million, up from $10.8 million in 2024.
• Research and development expenses surged by 280% to $24.0 million for the nine months ended September 30, 2025, primarily driven by the PMN310 Phase 1b clinical trial.
• The company received $21.6 million in gross proceeds in July 2025 from discounted warrant exercises, private placements, and a registered direct offering, less $1.4 million in transaction costs.
• Cash balance as of September 30, 2025, was $15.4 million, up from $13.3 million at December 31, 2024.
• Current liabilities increased significantly to $12.2 million from $2.2 million at December 31, 2024, largely due to increased accrued liabilities for R&D.
• The company has an accumulated deficit of $119.7 million and negative cash flows from operations of $18.8 million for the nine months ended September 30, 2025.
• Management has identified a material weakness in internal control over financial reporting related to fair value calculations.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including substantial net losses, a high burn rate, and an explicit 'going concern' warning. While there are positive clinical developments like FDA Fast Track designation and trial enrollment progress, these are early-stage and do not offset the immediate and severe liquidity risks. The recent capital raise provides temporary relief but does not resolve the fundamental funding uncertainty.

Positives

• PMN310, the lead product candidate for Alzheimer's disease, received Fast Track Designation from the FDA in July 2025.
• Enrollment for Cohorts 1 and 2 of the Phase 1b PRECISE-AD clinical trial is complete, with Cohort 3 well underway and full enrollment expected by year-end 2025, maintaining a favorable safety profile.
• Successfully raised $21.6 million in gross proceeds in July 2025 through various financing activities, providing short-term liquidity.
• PMN267 (ALS) and PMN442 (MSA) product candidates are ready to progress to IND-enabling studies, subject to sufficient resources.
• Slanix Paul Alex, Pharm.D., was appointed to the Board of Directors in October 2025.

Negatives

• Reported a net loss of $29.0 million for the nine months ended September 30, 2025, a substantial decline from a net income of $3.0 million in the prior year period.
• Operating losses significantly increased to $29.4 million for the nine months ended September 30, 2025, compared to $10.8 million in the same period of 2024.
• Current liabilities increased by over $10 million, from $2.2 million at December 31, 2024, to $12.2 million at September 30, 2025, primarily due to accrued research and development expenses.
• Accumulated deficit reached $119.7 million as of September 30, 2025.
• Negative cash flows from operations amounted to $18.8 million for the nine months ended September 30, 2025.
• Management believes conditions raise substantial doubt about the company's ability to continue as a going concern within the next twelve months.
• Identified a material weakness in internal control over financial reporting related to fair value calculations.

Risks

• Substantial doubt about the company's ability to continue as a going concern within the next twelve months due to incurred losses and ongoing funding needs.
• Requirement for substantial additional financing to fund future clinical activities, research and development, regulatory approvals, manufacturing, and marketing, with no assurance of obtaining it on acceptable terms.
• Risk of delays, reductions, or elimination of research and development programs, product portfolio expansion, or commercialization efforts if additional funding is not secured.
• Material weakness in internal control over financial reporting related to insufficient review controls over fair value calculations, which could lead to material misstatements.
• Potential adverse effects from changes to U.S. fiscal, tax, and other federal policies, including tariffs and tax law changes.
• Exposure to liquidity risk due to reliance on external fundraising and purchasing obligations.

Future Outlook

The company expects to incur net losses for at least the next several years as it advances product candidates and anticipates increased research and development, general and administrative expenses, and capital expenditures if additional funding is secured. It will require substantial additional funding to support continuing operations and growth strategy, aiming to finance through equity sales, debt, at-the-market programs, or collaborations, with no assurance of success on acceptable terms.

Management Comments

• Management believes these conditions raise substantial doubt about the Company's ability to continue as a going concern within the next twelve months from the date these unaudited condensed consolidated financial statements are issued.
• We expect to continue to incur net losses for the foreseeable future and, if able to raise additional funding, would expect our research and development expenses, general and administrative expenses and capital expenditures to increase.
• We will need substantial additional funding to support our continuing operations and pursue our growth strategy.
• We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all.
• If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, reduce or eliminate the development and commercialization of one or more of our product candidates or delay our pursuit of potential in-licenses or acquisitions.
• As of November 12, 2025, we have enrolled all of Cohorts 1 and 2 and are well into Cohort 3, with complete enrollment expected before the end of the year and a continued favorable safety profile.
• We anticipate reporting six-month interim data from the study in the second quarter of 2026, with topline results expected in the fourth quarter of 2026.

Industry Context

ProMIS Neurosciences operates in the highly capital-intensive neurodegenerative disease biotechnology sector, focusing on Alzheimer's, ALS, and MSA. The company's strategy of targeting misfolded proteins with selective antibodies aligns with a key area of research in these complex diseases. The FDA's Fast Track Designation for PMN310 highlights the significant unmet medical need in Alzheimer's, a common challenge across the industry. However, like many development-stage biotechs, the company faces substantial liquidity risks and relies heavily on external financing to fund its extensive and costly clinical development programs.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material litigation or legal proceedings that are likely to have a material adverse effect on the business.

Related Party Transactions

• UBC Collaborative Research Agreement: Amended in December 2024 to extend through February 2026, increasing aggregate funding to C$5,830,000. The company's Chief Scientific Officer is the principal investigator at UBC.
• UBC Agreement (February 2009, amended October 2015): Company committed to annual license fees (C$25,000 paid in 2025 and 2024) and royalty payments based on revenue from licensed technology, developed in part by the Chief Scientific Officer.

Stakeholder Impact

• Shareholders: Face significant dilution risk from ongoing and future equity financings, as well as substantial risk to investment due to the "going concern" warning and accumulated deficit.
• Employees: Potential impact on job security if funding is not secured, leading to delays, reductions, or elimination of programs.
• Creditors: Increased risk due to the company's substantial losses and "going concern" status, potentially affecting ability to meet obligations.
• Customers/Patients (future): Potential delays or termination of product development programs could impact the availability of future therapies for neurodegenerative diseases.

Next Steps

• Complete enrollment of Cohort 3 for the PMN310 Phase 1b PRECISE-AD clinical trial before the end of 2025.
• Report six-month interim data from the PRECISE-AD study in the second quarter of 2026.
• Report topline results from the PRECISE-AD study in the fourth quarter of 2026.
• Advance PMN267 (ALS) and PMN442 (MSA) to IND-enabling studies, subject to sufficient resources.
• Continue to progress with earlier stage preclinical programs, including amyloid and alpha-synuclein vaccine candidates.
• Refine the discovery algorithm using machine learning capabilities.
• Seek additional funding through public and private financings, debt financings, collaboration agreements, strategic alliances, and licensing agreements.
• Remediate the identified material weakness in internal control over financial reporting.

Key Dates

Recommendation

The company explicitly states "substantial doubt about its ability to continue as a going concern" within the next twelve months, driven by significant net losses ($29.0 million YTD Sep 2025) and negative cash flow from operations ($18.8 million YTD Sep 2025). While recent capital raises provided $21.6 million in gross proceeds, the burn rate is high, and the need for substantial additional funding is ongoing with no assurance of success on acceptable terms. The identified material weakness in internal controls adds to operational risk. Despite positive clinical progress for PMN310 (Fast Track designation, trial enrollment), these are early-stage developments that do not mitigate the immediate and severe financial viability concerns. A seasoned investor would prioritize capital preservation given the high financial risk.

Keywords

Neurosciences, Alzheimer's Disease, ALS, MSA, PMN310, PMN267, PMN442, Monoclonal Antibody, Clinical Trial, Phase 1b, Fast Track Designation, SEC Filing, 10-Q, Biotechnology, Drug Development, Going Concern, Capital Raise, Warrants, Research and Development, Financial Reporting, Corporate Governance